argenx to Present at Wells Fargo Healthcare Conference

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 7, 2022, at 8:00 a.m. E.T. in Boston, MA. The presentation will be accessible via live webcast on the Investors section of the argenx website, with a replay available for 90 days. argenx focuses on treating severe autoimmune diseases and is known for developing the first approved neonatal Fc receptor blocker in the U.S., EU, and Japan, while also advancing multiple experimental medicines.

August 31, 2022

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

FAQ

When is argenx participating in the Wells Fargo Healthcare Conference?

argenx will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 8:00 a.m. E.T.

Where can I watch the argenx presentation from the Wells Fargo Healthcare Conference?

The presentation can be accessed via live webcast on the Investors section of the argenx website.

What is the duration for which the argenx webcast will be available?

The replay of the argenx webcast will be available for approximately 90 days following the presentation.

What type of diseases does argenx focus on?

argenx is focused on developing treatments for severe autoimmune diseases.

What is notable about argenx's product development?

argenx developed the first-and-only approved neonatal Fc receptor blocker in the U.S., EU, and Japan.